Get Abivax alerts:Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report) – Stock analysts at Lifesci Capital boosted their FY2025 earnings per share (EPS) estimates for shares of Abivax in a report released on Monday, September 29th. Lifesci Capital currently has a “Outperform” rating and a $101.00 target price on the stock. Finally, Morgan Stanley boosted their price target on Abivax from $71.00 to $101.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Abivax Stock PerformanceShares of ABVX stock opened at $82.87 on Thursday. Octagon Capital Advisors LP purchased a new position in shares of Abivax in the 1st quarter valued at about $7,688,000.